24/01/2023 - Institutional news
The study is being led by Dr. Jaume Marrugat, a researcher at the IMIM-Hospital del Mar and coordinator of the Girona Heart Registry (REGICOR). It will analyse the association of the complete genome with the incidence of cardiovascular diseases in people who do not have this pathology and who have been under observation for more than ten years. This is the first project of its kind to be carried out in southern Europe, with a cohort of more than 101,000 participants from all over Spain, and will enable better personalised prevention of these pathologies in the country.
20/01/2023 - Press release
A person's biological age, in other words, the real age of their body, which is independent of chronological age and which can be measured in specific blood tests, is conditioned by their lifestyle habits. A study by the Neurovascular Research Group at the Hospital del Mar Medical Research Institute, published in the journal Biology, has for the first time associated a higher biological age with the presence of an indicator of brain ageing, white matter hyperintensities, areas of the brain that blood has a harder time reaching. Lifestyle habits influence the DNA configuration and determine biological age. If these habits are modified, DNA ageing and, therefore, biological ageing can be slowed down, thereby decelerating the increase in white matter hyperintensities in brain tissue.
18/01/2023 - General information
The Integrated Pharmacology and Systems Neurosciences Research Group of the Hospital del Mar Medical Research Institute has just published a study in Neurobiology of Disease, in which it highlights the role of the CDK5 protein as a possible marker of early psychosis. Furthermore, this protein is modulated by cannabis use. This paves the way for possible future treatments based on CDK5 expression.
Més informació "Possible biomarker for early psychosis identified"
13/01/23 - Events
The meeting, a success in terms of participation with more than 120 registered participants, has served to analyze the activity of the program and the strategic lines of growth. The Cancer Research Program of the Hospital del Mar Medical Research Institute held its annual meeting this morning, during which the main lines of the program were analyzed and the main challenges for the future were discussed. The initiative has been a success, with more than 120 people registered in the Josep Marull Room.
11/01/2023 - Press release
A study led by researchers from the Stem Cell and Cancer Research Group at the Hospital del Mar Medical Research Institute has revealed the key role a protein plays in identifying patients with T-cell acute lymphoblastic leukaemia who will not respond to standard treatment. The study, published in the journal EMBO Molecular Medicine, shows that combining chemotherapy with an inhibitor for this protein helps to eliminate treatment resistance in an animal model. This is a rare disease, which is diagnosed in around a hundred people each year in Spain, mainly paediatric patients.
22/12/2022 - Institutional news
The Hospital del Mar Medical Research Institute closes a 2022 in which it has strengthened its commitment to the pursuit of quality and the attraction of scientific talent of excellence and young researchers with initiatives such as the new OpenLab. 2022 has been a year full of good news for IMIM-Hospital del Mar. The research carried out has obtained results of great relevance and has had repercussions not only in scientific publications, but also in our society.
22/12/2022 - Institutional news
The European Medicines Agency selected Hospital del Mar Medical Research Institute and the Hospital del Mar to be a Data Partner of the DARWIN EU® data network, an EU-wide federated network of high-quality observational healthcare databases across Europe, that provides expertise and services to support regulatory decision-making throughout the lifecycle of medicinal products. The Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) is one of the first eight European centres currently selected to participate in the European Union's DARWIN EU® initiative to carry out multicentre observational studies on medicines. The data available to these partners will be used for studies to generate real-world evidence that will support scientific evaluations and regulatory decision making.
21/12/2023 - Events
Research into immunotherapy for cancer at the Hospital del Mar Medical Research Institute has received a new boost thanks to a donation of 43,250 euros from the Amics de l’Hospital del Mar Foundation. The president of the Amics de l’Hospital del Mar Foundation, Xavier Trias, presented the cheque to the young researchers Marta Bort, Laura Ibáñez and Iván Pérez, on behalf of the research team looking into the Role of Interferon-Gamma in T cell-mediated elimination of breast cancer tumour cells, a project selected through the internal call for proposals "immunotherapy seed". This initiative is aimed at studying, through a proof of concept, some of the molecular mechanisms used by tumour cells to resist immunotherapy, with the goal of improving breast cancer treatments.
20/12/2022 - General information
The Board of Trustees of the Spanish Psychiatry and Mental Health Foundation has chosen Dr. Víctor Pérez, head of the Psychiatry Department of the Hospital del Mar and coordinator of the Mental Health Research Group of the Hospital del Mar Medical Research Institute, as the new president of the organization. This appointment comes after Dr. Perez left his position as president of the executive committee of the Spanish Society of Psychiatry and Mental Health. As the highest representative of the foundation, Dr. Pérez will be responsible for representing the entity, chairing the meetings of its board of trustees and executing the agreements reached. The aim of its activity is to contribute to the knowledge, development and improvement of psychiatry and mental health and the disciplines that are linked to it.
Més informació "Dr. Víctor Pérez will chair the Spanish Foundation of Psychiatry and Mental Health."
02/12/2022 - Press release
The Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome. The study is part of the ICOD project for the improvement of cognition in Down syndrome, promoted by the European Union, which is funding a project of this type for the first time. The treatment has already passed the trial phase with volunteers without Down syndrome, which sought to certify the safety and tolerability of the medicine. In this new phase, the safety of the treatment in people with Down syndrome will be validated and the first indications of effectiveness will be obtained. It is estimated that results may be available by mid-2023.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact